Human CD22 Monoclonal Antibody

Größe

£486.00

SKU:: YR0113
Zusätzliche Namen:: SIGLEC-2|SIGLEC2
Anwendung:: ELISA, FuncS, Neutralisation
Molekulargewicht:: 150 kDa
Reinheit:: >95%
Lagerbedingungen:: 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
Hersteller:: Abclonal
Immunogen:: Human CD22
Formulierung:: Purified from cell culture supernatant in an animal-free facility
Uniprot:: P20273
Synonyme:: B-cell receptor CD22;B-lymphocyte cell adhesion molecule;BL-CAM;CD22 antigen;sialic acid-binding Ig-like lectin 2;SIGLEC-2;SIGLEC2;T-cell surface antigen Leu-14
Weitere Details:: Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).